Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. ACN
5. IBM
6. META
7. SPY
8. NVDA
9. PRIM
10. PFE

Go back to Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Raymond James Reiterates Strong Buy Rating on Trevi Therapeutics (TRVI)

March 19, 2025 7:22 AM EDT

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $29.00 price target on Trevi Therapeutics (NASDAQ: TRVI).

The analyst comments "We remain Strong Buy rated on TRVI following 4Q24 earnings. Our bullish thesis that Haduvio could potentially become the go-to... More